



Q4 and Full-Year Fiscal 2022 Financial Results and Corporate Update

NurExone Biologic Inc.
TSXV: NRX
FSE: J90



NUREXONE BIOLOGIC:

**Pioneering Exosome Therapy to Revolutionize
Recovery from Nervous System Injuries**



Company Overview

1. **Developing the ExoPTEN** - biologically-guided drug for patients with acute spinal cord injuries
2. **Proprietary ExoTherapy platform** for producing and loading exosomes with pharmaceutical cargo
3. **Listed on the Toronto Stock Exchange** - Venture and traded on the Frankfurt and other German Stock Exchanges markets.

Groundbreaking Research and Product Development

1. **Investigational drug ExoPTEN** demonstrated effective treatment in 75% of paralyzed rats in preclinical study
2. **Focus on minimally-invasive**, intranasal treatment of acute spinal cord injuries (SCI)
3. **Unique position in the industry** with both product in development and production and technology platform
4. **Technology and production platform** with potential for additional indications and partnering opportunity

FINANCIAL PERFORMANCE IN 2022

NurExone's financial performance demonstrates its commitment to research and development, as well as its financial stability as the company continues to advance its groundbreaking ExoTherapy platform and ExoPTEN drug.



Investment Growth

1. **R&D investment** increase by 142.8% from US\$0.57 million in 2021 to US\$1.39 million in 2022
2. **Cash position** growth by 11.1% from US\$2.21 million in 2021 to US\$2.46 million in 2022
3. **Working capital** increase by 78% from US\$1.18 million in 2021 to US\$2.10 million in 2022

Financial Results

1. **Losses of US\$8.17 million in 2022**, a 396.0% increase over 2021's US\$1.654 million loss
2. **General & Administrative Expenses:** US\$4.15 million in 2022, up from US\$1.14 million in 2021
3. **Listing Expenses:** US\$2.08 million, including reverse takeover acquisition, net liabilities, and legal costs

STRENGTHENED FINANCIAL POSITION AND CORPORATE ACHIEVEMENTS IN 2022



Cash Position and Working Capital

Successful debt settlement, completed on December 6, 2022

Cash position
increased by
11.1% from 2021
reaching

us\$2.46M

in 2022

Working capital
stands at

us\$2.10M

a 78% increase
over 2021

Corporate Milestones

Listing on TSX-V
in July 2022.
Successful reverse
takeover acquisition
of EnerSpar Corp.
shares

Ongoing research
and development
investments for
innovative
therapeutic
solutions

Strategic
collaborations and
partnerships with
industry players for
certain technology
aspects

Pre-clinical studies
of ExoPTEN in
paralyzed rats and
efficiency studies of
ExoTherapy
platform

Q4 2022: FINANCIAL HIGHLIGHTS: Steady Investment in R&D



1

Research and Development Expenses

US\$0.30 million in Q4 2021 to US\$0.38 million in Q4 2022. Increase due to extensive R&D efforts for siRNA-PTEN technology and other siRNA targets

2

General and Administrative Expenses

US\$0.61 million in Q4 2021 to US\$0.46 million in Q4 2022

3

Financial Expenses

US\$0.01 million in Q4 2021 to US\$0.17 million in Q4 2022. Increase due to change in accounting policy for warrant derivatives


4

Debt Settlement

- Completed on December 6, 2022
- Aggregate amount: CAD\$46,523.69
- Issuance of 122,430 common shares at CAD\$0.38 per share

ExoPTEN: A BREAKTHROUGH IN SPINAL CORD INJURY TREATMENT

NurExone's ExoPTEN drug and ExoTherapy platform are at the forefront of developing innovative solutions for patients with acute spinal cord injuries and other Central Nervous System (CNS) indications.



ExoPTEN A Promising Investigational Drug

- Targeting acute spinal cord injuries (SCI) via intranasal administration
- Effective treatment in 75% of paralyzed rats with spinal cord injuries
- Significant motor, reflex, and sensory improvements observed in preclinical studies
- Potential for functional recovery in the Central Nervous System (CNS)

ExoTherapy A Revolutionary Therapeutic Platform

- Proprietary technology for manufacturing and loading exosomes with pharmaceutical cargo
- Potential wide applicability for addressing various indications with significant larger market size

Market Impact and Opportunities

- Capitalizing on the US\$2.9 billion market for acute Spinal Cord Injuries (SCI)
- Efficient and cost-effective large-scale exosome production for \$2.3B exosome based technology market (Diagnostic and Therapeutic)
- Strengthening competitive edge through ongoing research and development efforts and strategic collaborations

INTELLECTUAL PROPERTY AND ORGANIZATIONAL GROWTH

Introduction: In this section, we will discuss NurExone's organizational development and expansion of its intellectual property portfolio. These developments showcase NurExone's dedication to maintaining a competitive advantage in the biopharmaceutical industry and assembling a world-class team to propel its innovative solutions forward.



Organizational Growth and Team Development

1. **25% increase in headcount** from the end of 2021, reaching over 12 employees as of December 31, 2022
2. **Largest department:** Scientific Development, with four full-time researchers and four part-time employees
3. **Commitment to building** a world-class team and cutting-edge product development for delivering innovative solutions to patients in need

Intellectual Property Expansion

1. **Notice of allowance** received for U.S. Patent Application NO. 17/042,441
2. **Seven intellectual properties in total**, including allowed U.S. patent, two PCT patent applications, and four provisional patents
3. **Continuous expansion of patent portfolio** to solidify a competitive moat in the industry



THANK YOU

For more information please contact:

Dr Lior Shaltiel, CEO: + 972 52 4803034

eMail: lior@nurexone.com

Yoram Drucker, VP Strategic Operations: + 972 54 4711171

eMail: yoram@nurexone.com

Investor Relations: +1 905 347 5569

eMail: IR@nurexone.com

DISCLOSURE

The matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the company could differ significantly from those statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

This document does not constitute an offer to sell or a solicitation of offers to buy any securities of the company or any entity.